ClinicalTrials.gov
public full text
Public Domain
Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer
Lugol's solution staining was regarded as a gold standard to detect early superficial lesion during esophageal cancer screening using endoscopy. However, the sensitivity and specificity were influenced by mucus and food debris of esophagus. Pronase, a kind of protease, was previously shown to improve the visibility of gastrointestinal tract. It's unknown if the pre-treatment with pronase would also improve the quality of iodine staining in esophagus.A randomized double-blind clinical trial was designed to investigate whether or not pronase might improve detection rate of early esophageal lesion, especially high grade dysplasia and early cancer by improving the esophageal visibility.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Impact of Timing of Premedication on Mucosal Visibility During Endoscopy-A Randomized Controlled Trial#830014
- Non-invasive Testing for Early oEesophageal Cancer and Dysplasia#860773
- Gastric In Vivo Study#879443
- Comparison of pCLE and EB in Gastric Lesion Diagnosis#876491
- Esophageal Protocol for Detection of Neoplasia in the Digestive Tract#1045922
Record · ID 1030369
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive